Moderate Established

Mô tả

Amlodipine inhibits CYP3A4-mediated simvastatin metabolism, increasing simvastatin plasma concentrations and the risk of statin-associated myopathy and rhabdomyolysis.

Cơ chế

Simvastatin acid is primarily metabolised by CYP3A4; amlodipine is a weak-to-moderate CYP3A4 inhibitor that reduces simvastatin clearance, increasing systemic exposure.

Ý nghĩa lâm sàng

FDA has limited the maximum simvastatin dose to 20 mg/day when combined with amlodipine to reduce myopathy and rhabdomyolysis risk.

Xử trí

Do not exceed simvastatin 20 mg/day when co-administered with amlodipine; consider switching to a statin not dependent on CYP3A4 (pravastatin, rosuvastatin) if higher statin intensity is needed.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.